Rabies virus, the prototype of the genus Lyssavirus, is highly neurotropic and remarkable in its ability to infect and kill all warm-blooded mammals. Protection against lethal infection can be achieved by pre-or, frequently, postexposure vaccination. Under these two conditions, as well as in experimental infections in unvaccinated animals, protection correlates with the presence of serum neutralizing antibody specific for the external glycoprotein (G) (3, 4, 8, 10, (17) (18) (19) 31) . Recently, several studies have also shown that the internal nucleoprotein (N) expressed in a recombinant virus vaccine (12, 19, 29) or inoculated as purified protein (13) protects mice and dogs against lethal rabies virus infections. The mechanism(s) of protection elicited by N is unclear. For example, Fu and coworkers (13) demonstrated that purified N induced rabies virus-specific helper T cells and priming of mice with N augmented the production of anti-G virus neutralizing antibody following rabies virus infection. Sumner and coworkers (29) , however, did not detect augmented anti-G neutralizing antibody titers following rabies virus challenge of mice that had been vaccinated with N. Furthermore, we were unable to detect anti-G neutralizing antibody by radioimmunoprecipitation or the standard rapid fluorescent-focus inhibition test (28) in A/WySnJ mice that had been vaccinated with a recombinant raccoon poxvirus (RCN) expressing N (RCN-N) or mice similarly vaccinated with RCN-N and then challenged with rabies virus (19) .
In order to investigate the mechanism(s) of resistance * Corresponding author.
induced by RCN-N, in this study sera of mice immunized by infection with this poxvirus expressing the N protein were examined for anti-rabies virus inhibitory and protective activity. Using a series of different assays and a more sensitive in vitro test, we demonstrate that anti-N antibody protects mice against lethal rabies virus challenge and has antiviral activity in vitro. Possible mechanisms explaining how antibody to this internal structural protein interacts with rabies virus are discussed.
MATERLALS AND METHODS
Mice. A/WySnJ mice were purchased from the Jackson Laboratory, Bar Harbor, Maine, and maintained as inbred stock at the Rocky Mountain Laboratories. Female (1, 30) . Production of RCN recombinants expressing the rabies virus N protein or G protein has been described previously (10, 11, 29) . Human TK-143B cells (21) were used for propagation of RCN and RCN rabies virus recombinants, which were then RABIES VIRUS ANTINUCLEOPROTEIN ANTIBODY purified by sedimentation in sucrose gradients as described by Esposito et al. (11) . Mouse neuroblastoma (MNB) cells infected with ERA rabies virus were used to detect antibodies against the rabies virus structural proteins in mouse sera by radioimmunoprecipitation assays with 35S-labeled viral proteins. Chicken-embryo-related (CER) cells (27) were utilized as indicator cells in the in vitro viral inhibition assay and to quantitate virus in a focal immunofluorescence assay (26) .
Radioimmunoprecipitation. Twelve 75-cm2 tissue culture flasks (Coming Glass Works, Coming, N.Y.) containing 2.4 x 108 MNB cells were infected with ERA rabies virus at a multiplicity of infection of 1. Thirty-eight hours later, the cells (2 x 107) in each flask were radiolabeled for 2 h in 5 ml of methionine-free medium containing 42 ,uCi of [35S]methionine. The cells were lysed in unlabeled lysing buffer at a concentration of 106 cells per ml (19) . Five microliters of undiluted serum was reacted with 0.5 ml of cell lysate.
Immunoprecipitates were bound to Pansorbin cells (Calbiochem Corporation, La Jolla, Calif.), centrifuged, and washed three times. The pelleted proteins were denatured for 10 min at 95°C, centrifuged, and then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (6) .
Vaccination, collection of sera, and quantitation of virus. h after virus was protective. As with the data in Table 1 , the resistance elicited by the anti-N sera was statistically significant but was not as complete or as persistent as that of the anti-G sera (data not shown).
These intriguing in vivo results demonstrating protective activity of antisera specific for a protein thought to be hidden within virus particles led us to be cautious and to perform several additional tests to confirm that anti-G neutralizing antibody was not present in the anti-N sera. The pools of anti-N sera were obtained from mice that had been vaccinated with RCN-N but had not been challenged with rabies virus. Thus, we were confident that they did not contain anti-G neutralizing antibody that may have been produced by an inadequately vaccinated mouse in response to a rabies virus challenge. Furthermore, anti-G antibody was not detected in the anti-N sera following SDS-PAGE analysis with [35S]methionine-labeled proteins of RCN-G or ERA rabies virus-infected cells (data not shown), and an exhaustive search for anti-G antibody with the highly sensitive indirect immunofluorescence assay using 143B cells infected with RCN-G also failed to detect anti-G antibody in the anti-N sera (data not shown).
In vitro assessment of anti-N antiviral activity. We proceeded then to study the antiviral inhibitory activity of the anti-N sera in vitro. In our initial experiments, target cells were incubated with undiluted anti-N sera for 1 h at 37°C and then challenged with virus. No protection of the cells was detected (data not shown). Next, we incubated virus and antisera before infecting the target cells (see Materials and Methods). The data in Fig. 1 illustrate that the anti-N sera readily inhibited virus replication and that it was markedly affected by dilution. For example, infectious virus was not detected through 96 h postinfection in cultures infected with mixtures of virus and anti-N sera diluted 1:2 (Fig. 1A) . Strong but less persistent antiviral activity also was detected with anti-N sera tested at 1:10 ( Fig. 1B) . At this dilution, infectious virus was not detected in cultures at 24 h but was present at 48 h, and the titer steadily increased thereafter. Importantly, at all intervals tested, the inhibition of viral replication in cultures infected with mixtures of virus and anti-N sera diluted 1:2 or 1:10 was consistently .99% (2 log1o units) compared with control cultures. Although the antiviral activity of anti-N sera diluted 1:50 was not as marked as that of the higher concentrations of sera (Fig. 1A and B), virus replication was inhibited >90% at the 24-, 48-, and 72-h intervals (Fig. 1C) . In contrast to anti-N serum, similar dilutions of anti-G serum had no effect on its ability to neutralize 100% of the viral infectivity.
Removal of antiviral activity from anti-N sera through absorption with anti-mouse Ig. Since the data now clearly illustrated that anti-N serum was protective in vivo and inhibited rabies virus replication in vitro, we set about to determine whether the anti-N antibody in these sera was the protective factor. Initially, anti-N and anti-G sera were absorbed with an equal volume of undiluted normal goat serum or goat anti-mouse Ig sera and then tested in the in vitro viral inhibition assay. Viral replication comparable to that of the virus control was detected at 24 h in monolayers infected with virus that had been mixed with anti-N or anti-G sera previously absorbed with goat anti-mouse Ig sera (Fig.   2 ). In contrast, anti-N and anti-G sera absorbed with normal goat serum completely inhibited replication at this interval. However, replication was detected in the presence of anti-N at 48 and 72 h. Similar results were previously detected at 48 and 72 h with unabsorbed anti-N (Fig. 1B) Fig. 1 . FFU, focus-forming units.
an extremely high neutralization titer of 1:10,240 and contained 256 IU of neutralizing antibody as assayed by the standard rapid fluorescent-focus inhibition test, failed to inhibit viral replication at any interval following absorption with the goat anti-mouse Ig. In contrast, this anti-G serum remained 100% inhibitory through 72 h following absorption with normal goat serum. We also determined that virus mixed with anti-N or anti-G serum absorbed with goat anti-mouse Ig serum did not protect mice in the FP assay whereas similar sera absorbed with normal goat sera remained protective (data not shown).
SDG analysis of anti-N serum. Elimination of the viral inhibitory activity from anti-N serum following absorption with goat anti-mouse Ig suggested that antibody was the responsible factor. To corroborate this result with a positive assay, the anti-N serum was subjected to SDG ultracentrifugation. Following dialysis, several fractions from the SDG were tested in the in vitro viral inhibition assay. The qualitative results are shown beneath the fraction number in Fig.  3 , and the quantitative data, expressed kinetically for the 72-h assay, are shown in Table 2 . Figure 3 illustrates that the anti-rabies virus inhibitory activity and the peak concentration of rabbit gamma globulin were present in fraction 11. Although a minimal amount of viral replication was detected at the 24-h interval with fraction 11, the inhibition was quantitatively similar to those of the unfractionated anti-N serum at 24 h (.90%) and 48 and 72 h (.99%) ( Removal of antiviral inhibitory activity from anti-N sera through absorption with N antigen. To determine unequivocally that the antiviral factor was specifically anti-N antibody, anti-N sera were absorbed with S. frugiperda cells infected with the baculovirusA. californica expressing the N protein (SF9-N). Absorption of anti-N sera with SF9-N cells completely removed the anti-N antibody, as determined by radioimmunoprecipitation and SDS-PAGE analysis (Fig. 5) , whereas similar absorption with normal SF9 cells not expressing N failed to remove the antibody. Absorbed sera were subsequently tested in both the in vivo protection and the in vitro viral inhibition assays. Rabies virus replication was not inhibited with anti-N sera that did not contain anti-N antibody (Fig. 6) . In contrast, anti-N sera containing anti-N antibody following absorption with normal SF9 cells inhibited viral replication as well as the unabsorbed anti-N sera. Similar results were obtained with the absorbed sera in the in vivo FP protection assay (data not shown). Thus, we are confident that it is anti-N antibody in anti-N sera that is inhibitory for rabies virus and protects mice against a lethal infection. Why the antiviral effect wanes somewhat with time is unclear. Nonetheless, these data indicate that anti-N antibody is a component of the resistance to rabies virus infections.
DISCUSSION
The results presented herein demonstrated through physical and immunological selection procedures that rabies virus anti-N antibody present in sera of mice vaccinated with RCN-N was protective in vivo and had in vitro viral inhibitory activity. In contrast to our results, the in vivo studies of Schumacher and coworkers (25) showed that pretreatment of mice with monoclonal antibodies to the rabies virus ribonucleoprotein complex had no protective effect on an intramuscular rabies virus challenge. These contrasting results may be explained by the different routes of virus challenge, the concentrations of antibody and virus used, or VOL. 67, 1993 on August 27, 2017 by guest http://jvi.asm.org/ Downloaded from a SDG analysis of anti-N sera was done with 4-ml linear 10 to 37.5% sucrose gradients (see Materials and Methods). Following dialysis, gradient fractions, in addition to appropriate controls, were tested in the in vitro viral inhibition assay (see the legend to Fig. 1) . FFU, focus-forming units; Neg, negative. the fact that in our studies anti-N antibody and virus were either preincubated prior to FP inoculation or inoculated into the same site. Nonetheless, it is well established that animals vaccinated with purified N protein (13) or recombinant viruses expressing the N protein (12, 19, 29) are well protected against rabies virus infections. Although a mechanism for N-induced protection has not been previously reported, it was suggested by Fu and coworkers (13) Presently, we do not understand how antibody to an internal viral protein protects mice from infection and inhibits viral replication in vitro. Because we showed that preincubation of target cells with anti-N sera prior to infection did not inhibit viral replication, it appears unlikely that the effect of the anti-N antibody was to inhibit virus attachment to cell receptors or to inhibit intracellular viral transcription, as has been shown with scrape-loaded anti-N monoclonal antibody (16) . Our data also showed that the antiviral activity of anti-N sera could be demonstrated only following a direct interaction between antibody and virus. How does one envisage the inactivation of rabies virus by antibody to an internal structural viral protein? An obvious explanation, though unsubstantiated in the literature, is that N or a portion of the protein is present on the surface of the virus and is more accessible than previously thought. It is known that enveloped viruses such as rabies virus are generated by budding from the plasma membrane (5, 15) . Therefore, any viral component expressed on the surface of the virusreleasing cell could possibly be present on the surface of the virion. In support of this possibility, Bruns et al. (2) demonstrated that the viral envelope of the intact lymphocytic choriomeningitis virion which is generated by budding from the plasma membrane contains a nonglycosylated phosphorylated portion of the nucleoprotein. Thus, there is precedence for exposure of at least a portion of an internal nucleoprotein on the surface of an RNA enveloped virus. Alternatively, although we have been unable to detect any cross-reactivity between anti-G and anti-N antibodies by immunofluorescence or radioimmunoprecipitation and SDS-PAGE analysis, minor antigenic similarities between the N and G proteins might account for the viral inhibitory and protective activity of anti-N antibody. If so, the anti-N could interact with G on the surface of the virion. In support of this possibility, a comparison of the two protein sequences has indicated that three homologous regions exist (N. Tordo, personal communication; cited in reference 14) .
It is apparent from the results presented here and elsewhere that anti-N antibody is a component of the resistance to rabies virus that should not be ignored. Furthermore, it is known that the N protein is the most highly conserved protein of different rabies viruses (9, 24) . Because of this sequence conservation and protective activity, we suggest that N be considered for inclusion with G in future recombinant rabies vaccines and that antibodies to both proteins be included in antibody mixtures that may be used in rabies virus Ig serotherapy. assistance with the SDG; T. Ruark for care of the experimental animals; G. Hettrick and R. Evans for graphic arts assistance; and I. C. Rodriguez for secretarial assistance.
